Prognostic Influences of B-cell Lymphoma 2-positive Expression on Late Recurrence in Breast Cancer

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2023 Jul 13

PMID 37441325

Authors

Hee Ju Kim

Yong Hwa Eom

Seung Hye Choi

Affiliations

Soon will be listed here.

Abstract

Purpose: B-cell lymphoma 2 (BCL2) has an antiapoptotic role, however, has resulted in it being a powerful favorable prognostic factor in breast cancer. Several studies revealed BCL2 is strongly associated with a lower rate of early recurrence after initial treatment in breast cancer patients, but study of a prolonged effect after 5 years is lacking. We investigated BCL2 as a prognostic factor in breast cancer in comparison to early and late recurrence.

Methods: We retrieved data from 2,198 patients with primary breast cancer who underwent surgical treatment and adjuvant treatment at the breast cancer center between 2005 and 2015. Each molecular subtype was classified, and Ki-67 and BCL2 were also assessed by immunohistochemistry. BCL2 and the association between molecular subtypes were assessed in early and late recurrences, respectively. Five-year postrecurrence survival and BCL2 were also assessed.

Results: The BCL2-positive group was associated with favorable clinicopathologic characteristics. The time to recurrence was significantly longer in the BCL2-positive group (P = 0.035). Late recurrence after 5 years was higher in the BCL2-positive group (P = 0.029). In multivariate survival analysis, tumor size and BCL2-positive expression were the only independent prognostic factors for late recurrence (P = 0.004). In the patients with recurrence, 5-year postrecurrence survival was significantly higher in the BCL2-positive group (P < 0.001).

Conclusion: Our result showed that prognosis was better in BCL2-positive patients compared to BCL2-negative patients at late recurrence. We suggested that BCL2 expression could be used as a marker to help determine additional adjuvant therapy or extended hormone therapy in hormone-dependent breast cancer.

References

van Slooten H, Clahsen P, Van Dierendonck J, Duval C, Pallud C, Mandard A . Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996; 74(1):78-85. PMC: 2074622. DOI: 10.1038/bjc.1996.319. View

Wangchinda P, Ithimakin S . Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016; 14(1):223. PMC: 4995804. DOI: 10.1186/s12957-016-0988-0. View

Callagy G, Pharoah P, Pinder S, Hsu F, Nielsen T, Ragaz J . Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006; 12(8):2468-75. DOI: 10.1158/1078-0432.CCR-05-2719. View

Teixeira C, Reed J, PRATT M . Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995; 55(17):3902-7. View

Callagy G, Webber M, Pharoah P, Caldas C . Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008; 8:153. PMC: 2430210. DOI: 10.1186/1471-2407-8-153. View

Vogler M . Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med. 2015; 2014:943648. PMC: 4590949. DOI: 10.1155/2014/943648. View

Honma N, Horii R, Ito Y, Saji S, Younes M, Iwase T . Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer. 2015; 15:698. PMC: 4607008. DOI: 10.1186/s12885-015-1686-y. View

Murata T, Jinno H, Takahashi M, Shimoda M, Hayashida T, Kameyama K . Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence. Breast J. 2018; 25(1):9-15. DOI: 10.1111/tbj.13033. View

Foldi J, OMeara T, Marczyk M, Sanft T, Silber A, Pusztai L . Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. J Clin Oncol. 2019; 37(16):1365-1369. DOI: 10.1200/JCO.18.01933. View

10.

Dawson S, Makretsov N, Blows F, Driver K, Provenzano E, Le Quesne J . BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010; 103(5):668-75. PMC: 2938244. DOI: 10.1038/sj.bjc.6605736. View

11.

Hwang K, Kim Y, Kim J, Oh H, Park J, Choi I . Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer. Sci Rep. 2021; 11(1):11942. PMC: 8184896. DOI: 10.1038/s41598-021-90506-x. View

12.

Cory S, Huang D, Adams J . The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003; 22(53):8590-607. DOI: 10.1038/sj.onc.1207102. View

13.

Leone J, Vallejo C, Hassett M, Leone J, Graham N, Tayob N . Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021; 189(1):203-212. PMC: 8302525. DOI: 10.1007/s10549-021-06233-4. View

14.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

15.

Neri A, Marrelli D, Roviello F, DeMarco G, Mariani F, DeStefano A . Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat. 2006; 99(1):77-83. DOI: 10.1007/s10549-006-9183-2. View

16.

Fumagalli C, Barberis M . Breast Cancer Heterogeneity. Diagnostics (Basel). 2021; 11(9). PMC: 8468623. DOI: 10.3390/diagnostics11091555. View

17.

Zhang Y, Schnabel C, Schroeder B, Jerevall P, Jankowitz R, Fornander T . Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013; 19(15):4196-205. DOI: 10.1158/1078-0432.CCR-13-0804. View

18.

Silvestrini R, Veneroni S, Daidone M, Benini E, Boracchi P, Mezzetti M . The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994; 86(7):499-504. DOI: 10.1093/jnci/86.7.499. View

19.

Yang D, Chen M, Wang L, Yang L, Liu C, Lu P . Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis. J Exp Clin Cancer Res. 2013; 32:105. PMC: 3922829. DOI: 10.1186/1756-9966-32-105. View

20.

Pedersen R, Esen B, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash T . The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. J Natl Cancer Inst. 2021; 114(3):391-399. PMC: 8902439. DOI: 10.1093/jnci/djab202. View